Primary Care POC Diagnostics Market Size & Share Analysis Report By Product (Glucose Testing, Lipid Testing, Drug Abuse Testing), By End Use (Pharmacy & Retail Clinics, Physician Office), And Segment Forecasts, 2018 - 2025

Industry Insights

The global primary care POC diagnostics market size was estimated at USD 6.3 billion in 2016.Rapid evolution of point-of-care testing (POCT) holds enormous potential for the growth of both primary and secondary care settings. Rapidly increasing healthcare expenditure within secondary and tertiary care has driven the attention of healthcare communities toward primary care settings. This expenditure issues can be curbed to a great extent at the primary care stage through routine screening of patients with early symptoms. As a result, the market for primary care POC diagnostics is likely to receive a major boost. 

Companies within the market are undertaking continuous efforts for the advancement of POC products with respect to their portability and ease-of-use. This is mainly to ensure effective and unrestricted usage of POC devices at primary care levels and in remote settings with no/minimal laboratory infrastructure. In the current scenario, POCT is successfully implemented for disease diagnosis in outpatient settings, which include non-practice clinics, urgent care, and physicians’ offices and clinics.

Demand for POC technologies from primary care physicians is likely to grow significantly over the years. This is due to a paradigm shift in diagnostics from centralized labs towards practitioners’ offices, which in turn, would open new revenue streams for various end users and significantly improve profit margins. 

Higher adoption of POC testing in primary care is observed in remote locations as well as relatively densely populated regions where telehealth services are being actively considered to improve patient convenience. Decentralization of primary care services in several markets around the world has become a common trend as it helps reduce use of antibiotics and offers rapid results. This is expected to drive adoption of POCT in the market.

Growing usage of POCT in primary care settings can also be attributed to ease-of-usage associated with these devices in out-of-hospital laboratory settings. In addition, medical as well as nonmedical personnel can use these devices with minimum training.

Product Insights

POCT devices and products include primary care systems, feces testing, Hb1Ac testing, decentralized clinical chemistry, cardiac markers, hematology, fertility, lipid testing, cancer marker, urinalysis, coagulation, drug abuse testing, glucose testing, blood gas/electrolytes, thyroid stimulating hormone, infectious diseases, and ambulatory chemistry. Rising availability of these devices, ongoing studies on their usage, and continuous technological advancements are expected to drive the primary care POC diagnostics market.

Glucose testing is a major segment within the market. Adoption of self-testing glucose devices plays an important role in controlling glycemic levels on a regular basis, which, in turn, is anticipated to provide positive health outcomes, especially among diabetics.

Lipid testing products are expected to witness strong growth over the forecast period. Commercial availability of a number of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-waived POC lipid testing products in the market is likely to drive the segment considerably. F. Hoffmann-La Roche Ltd.’s Accutrend Plus system is a significant example of such testing products, which can be effectively employed in physicians’ offices and clinics. Ongoing research studies and support from funding agencies is also expected to boost the segment over the course of the forecast period.

End-use Insights

A global rise in POCT owing to easy and quick results has radically improved workflow and patient care at physicians’ offices. These tests, supported by the expertise of doctors in quickly assessing the situation and making important medical decisions, deliver improved clinical outcomes. POCT also aids in performing complex tests with low sample volumes compared to those performed in laboratories. Thus, factors such as consumer demand for easy, stress-free, and less time-consuming tests are likely to boost the market for primary care POC diagnostics in physicians’ offices.

The pharmacy and retail clinics segment is also expected to witness steady growth over the forecast period. Increase in the number of people covered under healthcare plans has resulted in reduction in healthcare costs and improved access to healthcare. This has led to the availability of POC testing at pharmacies. In the last five years, the number of pharmacists performing laboratory tests such as cholesterol screening and glycosylated hemoglobin (A1C) has increased. Moreover, an increasing number of patients prefer to undergo testing for acute and chronic diseases at pharmacies, thus providing the segment lucrative opportunities for growth.

Regional Insights

North America held the largest share in 2016 owing to a substantial number of primary care settings in U.S. that employ POC products. Presence of major players in the country offering products and services for primary settings has also attributed to the large share of this regional market. The Centers for Medicare & Medicaid Services is urging healthcare providers to initiate patient engagement programs. This, along with availability of funding for R&D in healthcare by universities and academia, is driving the market.

The North America market is relatively more developed compared to the rest of the world and this can be attributed to availability of numerous advanced and innovative POC diagnostic solutions. Growing demand for these solutions in primary home healthcare and assisted healthcare settings is also a key growth driver. Introduction of advanced healthcare solutions such as EHR, digitalization, and telemedicine also works in the market’s favor.

However, Asia Pacific is expected to emerge as a lucrative regional market and is slated to exhibit a stronger growth rate compared to other regions. This can be attributed to an increasing number of firms engaged in capitalizing untapped potential in the region. Moreover, growing awareness among the population about early disease diagnoses to imrpove patient survival rate is expected to spur the market in Asia Pacific.

Primary Care POC Diagnostics Market Share Insights

Some of the key players operating in the market are Roche Diagnostics, BD Biosciences, Danaher Corporation, Abbott Laboratories, Instrumentation Laboratory, bioMerieux, Siemens Healthcare, and Quidel Corporation.

Partnerships and agreements are a major trend observed in the market. These companies have been drafting agreements with prominent emerging participants in order to establish co-ownership in IP and to gain key licenses and sub-licenses from various universities for foundation IP rights. Companies are also engaged in collaborations with major players to develop new product lines and enhance their market presence.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global primary care POC diagnostics market report on the basis of product, end use, and region:

• Product Outlook (Revenue, USD Million, 2014 - 2025)

  • Glucose Testing

  • Hb1Ac Testing

  • Coagulation

  • Fertility

  • Infectious Diseases

  • Cardiac Markers

  • Thyroid Stimulating Hormone

  • Hematology

  • Primary Care Systems

  • Decentralized Clinical Chemistry

  • Feces

  • Lipid Testing

  • Cancer Marker

  • Blood Gas/Electrolytes

  • Ambulatory Chemistry

  • Drug Abuse Testing

  • Urinalysis

• End-use Outlook (Revenue, USD Million, 2014 - 2025)

  • Pharmacy & Retail Clinics

    • Pharmacy & Retail Clinics, By Product

      • Glucose Testing

      • Hb1Ac Testing

      • Coagulation

      • Fertility

      • Infectious Diseases

      • Cardiac Markers

      • Thyroid Stimulating Hormone

      • Hematology

      • Primary Care Systems

      • Decentralized Clinical Chemistry

      • Feces

      • Lipid Testing

      • Cancer Marker

      • Blood Gas/Electrolytes

      • Ambulatory Chemistry

      • Drug Abuse Testing

      • Urinalysis 

  • Physician Office

    • Physician Office, By Product

      • Glucose Testing

      • Hb1Ac Testing

      • Coagulation

      • Fertility

      • Infectious Diseases

      • Cardiac Markers

      • Thyroid Stimulating Hormone

      • Hematology

      • Primary Care Systems

      • Decentralized Clinical Chemistry

      • Feces

      • Lipid Testing

      • Cancer Marker

      • Blood Gas/Electrolytes

      • Ambulatory Chemistry

      • Drug Abuse Testing

      • Urinalysis

  • Urgent Care Clinics

    • Urgent Care Clinics, By Product

      • Glucose Testing

      • Hb1Ac Testing

      • Coagulation

      • Fertility

      • Infectious Diseases

      • Cardiac Markers

      • Thyroid Stimulating Hormone

      • Hematology

      • Primary Care Systems

      • Decentralized Clinical Chemistry

      • Feces

      • Lipid Testing

      • Cancer Marker

      • Blood Gas/Electrolytes

      • Ambulatory Chemistry

      • Drug Abuse Testing

      • Urinalysis

  • Non-practice Clinics

    • Non-practice Clinics, By Product

      • Glucose Testing

      • Hb1Ac Testing

      • Coagulation

      • Fertility

      • Infectious Diseases

      • Cardiac Markers

      • Thyroid Stimulating Hormone

      • Hematology

      • Primary Care Systems

      • Decentralized Clinical Chemistry

      • Feces

      • Lipid Testing

      • Cancer Marker

      • Blood Gas/Electrolytes

      • Ambulatory Chemistry

      • Drug Abuse Testing

      • Urinalysis

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • France

    • U.K.

    • Italy

    • Spain

  • Asia Pacific

    • China

    • Japan

    • India

    • Korea

    • Australia

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Chile

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Nigeria

    • Qatar

    • Kenya

    • Zimbabwe